Abstract
Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4′-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT (123I-CLINDE) and amino acid transport imaging using O-(2-18F-fluoroethyl)-L-tyrosine PET (18F-FET) and investigate whether 123I-CLINDE is superior to 18F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. Methods: Three patients with World Health Organization grade IV GBM were scanned with 123I-CLINDE SPECT, 18F-FET PET, and gadoliniumenhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans. Results: The percentage overlap between volumes of interest (VOIs) of increased 18F-FET uptake and 123I-CLINDE binding was variable (12%-42%). The percentage overlap of MR imaging baseline VOIs was greater for 18F-FET (79%-93%) than 123I-CLINDE (15%- 30%). In contrast, VOIs of increased contrast enhancement at followup compared with baseline overlapped to a greater extent with baseline 123I-CLINDE VOIs than 18F-FET VOIs (21% vs. 8% and 72% vs. 55%). Conclusion: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at followup and may be less susceptible to changes in blood-brain barrier permeability than 18F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of Nuclear Medicine |
Vol/bind | 56 |
Udgave nummer | 9 |
Sider (fra-til) | 1386-90 |
Antal sider | 5 |
ISSN | 0161-5505 |
DOI |
|
Status | Udgivet - 1 sep. 2015 |